Investigational drug · Phase 2
STSP-0902
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neurotrophic Keratitis, Oligozoospermia and/or Asthenozoospermia.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "STSP-0902"
First trial start
2025
Jun 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STSP-0902", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neurotrophic Keratitis
- Oligozoospermia and/or Asthenozoospermia
Largest trials
Live from ClinicalTrials.gov: studies naming "STSP-0902" as an intervention, largest first.
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT06597422 · 82 participants · Start Oct 20, 2024 · Primary completion Jan 23, 2025
Drug: STSP-0902 ophthalmic solution; STSP-0902 Placebo and 4 more · For: Neurotrophic Keratitis
Sites: Beijing, China
- A Study to Evaluate the Safety and Efficacy of Multiple Dose of STSP-0902 in Patients With Oligozoospermia and/or Asthenozoospermia.Not yet recruiting
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT07833943 · 72 participants (planned) · Start Sep 2026 · Primary completion Sep 2027
Drug: STSP-0902 injection; Placebo · For: Oligozoospermia and/or Asthenozoospermia
Sites: Beijing, China
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT06948799 · 64 participants (planned) · Start May 8, 2025 · Primary completion Jul 2026
Drug: STSP-0902 injection; Placebo · For: Oligozoospermia
Sites: Beijing, China
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT06975748 · 48 participants (planned) · Start Jun 12, 2025 · Primary completion Apr 2026
Drug: STSP-0902 ophthalmic solution; STSP-0902 ophthalmic solution and 1 more · For: Neurotrophic Keratitis
Sites: Jinan, China
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT06563713 · 40 participants · Start Jul 31, 2024 · Primary completion Feb 24, 2025
Drug: STSP-0902 injection; Placebo · For: Oligozoospermia; Asthenozoospermia
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Neurotrophic Keratitis
- KB801Phase 21 trial
Krystal Biotech, Inc. · Neurotrophic Keratitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.